Parathyroid cancer treatment with targeted therapy

Targeted therapy aims to impact some critical points inside the parathyroid cancer cells to stop the further growth and development of the tumor. As a result, the tumors begin to shrink, which creates an opportunity to remove cancer during surgery or use some other treatment method. In addition, targeted therapy might impact a specific protein, substance, or even gene, which is crucial for the normal functioning of cancerous cells. Currently, in most cases, doctors use a combination of targeted therapy with chemotherapy to achieve the best possible outcomes. Among the most widely used treatment tactics are: pembrolizumab, with immune checkpoint inhibitors; lenvatinib, with multi-receptor tyrosine kinase inhibition; and olaparib, with PARP inhibitors. Targeted medication can't be used for every patient. Therefore, a series of lab tests, examinations, and diagnostic procedures determine the most effective method of targeted therapy. A single course of targeted therapy often might show little results. Yet, it might be enough to see slight changes in the patient's condition. A single treatment session might take up to a few hours. The patient will receive medications via droppers or intravenous injections. On average, patients might need up to 8 - 10 procedures before noticing steady, sustainable improvement.